Members of the Scheller Lab in collaboration with the Milbrandt and DiAntonio groups at WashU published a paper in JCI Insight in which they found that loss of Sarm1 could completely protect female mice against the development of bone loss and severe osteoblast suppression secondary to type 1 diabetes. Sarm1 knockout also prevented neuropathy in males, independent of its effects on bone. Altogether, this work identifies Sarm1 as a candidate therapeutic target that, when inhibited, may protect against neural and skeletal complications in patients with type 1 diabetes. Sarm1 knockout prevents type 1 diabetic bone disease in females independent of neuropathy